百时美施贵宝 （Bristol Myers Squibb） 报告强劲的收益，但由于普遍的竞争压力下调了 2025 年的前景。 Bristol Myers Squibb reports strong earnings but lowers 2025 outlook due to generic competition pressures.

Bristol Myers Squibb报告Q4收入丰厚,但发布2025年指南,由于预期非专利药品会竞争旧药,因此低于预期。 Bristol Myers Squibb reported strong Q4 earnings but issued 2025 guidance that fell short of expectations due to anticipated competition from generics for older drugs. 该公司计划到2027年将成本减少20亿美元,以抵消收入损失并投资于增长机会。 The company plans to cut costs by $2 billion by 2027 to offset revenue losses and invest in growth opportunities. 尽管面临挑战,布里斯托尔·迈尔斯·斯基布期望通过扩大投资组合和业务改进,实现大量节约和维持增长。 Despite facing challenges, Bristol Myers Squibb expects to achieve significant savings and maintain growth through its expanding portfolio and operational improvements.